Mphasis Limited
MPHASIS.NS
₹2424.50
▼ 0.31%
Mphasis eased 0.31% to ₹2,424.50, a muted reaction to a June-quarter print that was solid on the top line but soft on execution—revenue grew 17.5% YoY to ₹4,384 crore, yet profit growth of 10.8% to around ₹489.5-509.6 crore came in below EPS estimates and fell sequentially. The company continued its streak of strong deal wins, with new TCV of $461 million marking the fifth consecutive quarter above the $400 million mark and 63% of that AI-led, though EBIT margin slipped 60 basis points QoQ to 14.8%. Nomura responded by trimming its target to ₹2,620 from ₹2,640 while keeping a Buy rating, whereas Nuvama stayed more bullish with a ₹3,200 target, arguing the stock's current 17x FY28E PE looks undemanding against its assigned 25x multiple. The stock has struggled over the medium term, down 11.60% over one year and 9.77% over two years, though the broader analyst consensus remains buy with an average target of ₹2,589.78 across 37 analysts.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| -11.60% | -9.77% | -3.14% | 16.28% |
Analyst Consensus
Average Target Price: ₹2589.78 (range ₹1720.00 - ₹3200.00) based on 37 analysts
Strong Buy: 8
Buy: 18
Hold: 6
Sell: 2
Strong Sell: 2
Related News
| Jan 22, 2026 | Mphasis Posts Q3 Consol Net Profit 4.42 Billion Rupees; IBES Est 4.82 Billion Rupees |
No comments:
Post a Comment